Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04338360
  4. Details
NCT04338360 Clinical Trial

Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

COVID19 Clinical Trial

Official title:
Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19

Clinical Trial Details — Status: Approved for marketing

Administrative data
NCT number NCT04338360
Other study ID # 20-003312
Secondary ID
Status Approved for marketing
Phase
First received
Last updated

Study information
Verified date August 2020
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

This expanded access program will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

Recruitment information / eligibility
Status Approved for marketing
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age at least 18 years

- Laboratory confirmed diagnosis of infection with SARS-CoV-2

- Admitted to an acute care facility for the treatment of COVID-19 complications

- Severe or life threatening COVID-19, or judged by the treating provider to be at high risk of progression to severe or life-threatening disease

- Informed consent provided by the patient or healthcare proxy

Severe COVID-19 is defined by one or more of the following:

- dyspnea

- respiratory frequency = 30/min

- blood oxygen saturation = 93%

- partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300

- lung infiltrates > 50% within 24 to 48 hours

Life-threatening COVID-19 is defined as one or more of the following:

- respiratory failure

- septic shock

- multiple organ dysfunction or failure

Exclusion Criteria:

- None

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• COVID-19 convalescent plasma
COVID-19 convalescent plasma

Locations
Country Name City State
United States Mayo Clinic Health System in Albert Lea Albert Lea Minnesota
United States Mayo Clinic Health System in Austin Austin Minnesota
United States Mayo Clinic Health System in Cannon Falls Cannon Falls Minnesota
United States Mayo Clinic Health System - Eau Claire Eau Claire Wisconsin
United States Mayo Clinic in Florida Jacksonville Florida
United States Mayo Clinic Health System - Franciscan Healthcare La Crosse Wisconsin
United States Mayo Clinic Health System in Lake City Lake City Minnesota
United States Mayo Clinic Health System in Mankato Mankato Minnesota
United States Mayo Clinic Health System in Owatonna Owatonna Minnesota
United States Mayo Clinic Health System in Red Wing Red Wing Minnesota
United States Mayo Clinic in Rochester Rochester Minnesota
United States Mayo Clinic in Arizona Scottsdale Arizona

Sponsors (1)
Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3

External Links